Skip to main content
. 2018 Dec 14;24(7):921–932. doi: 10.1634/theoncologist.2018-0344

Table 4. Overview of treatment‐emergent adverse events (safety population).

image

Abbreviations: cFOLFOXIRI‐BEV, concurrent 5‐fluorouracil/leucovorin/oxaliplatin/irinotecan plus bevacizumab; FOLFOX‐BEV, 5‐fluorouracil/leucovorin/oxaliplatin plus bevacizumab; sFOLFOXIRI‐BEV, sequential 5‐fluorouracil/leucovorin/oxaliplatin/irinotecan plus bevacizumab; TEAE, treatment‐emergent adverse event.